Cell and gene therapy in 2045
Shaping tomorrow’s market from today’s medicinal marvel
Report
Discover how to prepare your CGT organisation for the future.
The cell and gene therapy (CGT) market is advancing rapidly, yet many leaders lack a clear view of how to translate scientific progress into reliable, scalable delivery. Unpredictable regulatory direction, fragile manufacturing ecosystems, and long term viability of bespoke delivery models stall momentum, as well as high cost-to-serve versus uncertain adoption curves.
Our analysis cuts through the noise with a clear view of where the CGT landscape is heading, the risks and opportunities that matter, and the capabilities needed to win. The report explores:
- How scientific progress, operational capability, policy trends, and reimbursement pressures are reshaping the CGT landscape and how these forces play out across four possible future worlds
- Where emerging constraints and opportunities are most likely to influence development, manufacturing, access, and delivery
- Which areas that CGT leaders need to apply strategic focus to stay ahead of shifting expectations from regulators, payers, providers, and partners
- Insights into the capabilities that successful organisations will need to succeed.
Exploring four possible futures
Our research explores four possible future worlds for cell and gene therapy, each representing how different combinations of modality complexity and health system integration could shape the field. This analysis is designed to provoke thinking about how the future may unfold and how leaders can prepare for different pathways: to challenge assumptions, not predict inevitabilities.
The report combines our unique approach to scenario planning with insights from biochemists, biologists, mechanical engineers, materials specialists, healthcare experts, strategists, and more, to help CGT leaders look beyond today’s bottlenecks, build the capabilities needed to shape the market, and accelerate patient access.
How we can help
We partner with cell and gene therapy manufacturers, technology providers, pharma, biotechs and academic medical centres to maximise the potential and impact of advanced therapies.
Working at the intersection of technology, science, innovation, strategy, and healthcare, our teams resolve operational bottlenecks and prepare organisations for regulatory and market‑access milestones.
Explore more
